Evista and Hepatic encephalopathy - a phase IV clinical study of FDA data

Summary:

Hepatic encephalopathy is reported as a side effect among people who take Evista (raloxifene hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Portopulmonary hypertension.

The phase IV clinical study analyzes which people have Hepatic encephalopathy when taking Evista. It is created by eHealthMe based on reports of 25,442 people who have side effects when taking Evista from the FDA, and is updated regularly.

What is Evista?

Evista has active ingredients of raloxifene hydrochloride. It is often used in osteoporosis. eHealthMe is studying from 25,891 Evista users. Check the latest studies of Evista.

What is Hepatic encephalopathy?

Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure) is found to be associated with 909 drugs and 1,264 conditions by eHealthMe. Check the latest studies of Hepatic encephalopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

25,442 people reported to have side effects when taking Evista.
Among them, 16 people (0.06%) have Hepatic encephalopathy.

Could Evista cause Hepatic encephalopathy?

Among these 16 people:

How long have people been on Evista when they have Hepatic encephalopathy? *

What is the gender of people who have Hepatic encephalopathy when taking Evista? *

female: 93.75 %
male: 6.25 %

What is the age of people who have Hepatic encephalopathy when taking Evista? *

What are other drugs people take besides Evista? *

What are other side effects people have besides Hepatic encephalopathy? *

Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 7 people, 43.75%
Peritonitis Bacterial (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs by bacterial): 7 people, 43.75%
Ascites (accumulation of fluid in the abdominal cavity): 6 people, 37.50%
Disease Progression: 6 people, 37.50%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 5 people, 31.25%
Abdominal Tenderness: 5 people, 31.25%
Autoimmune Hepatitis: 5 people, 31.25%
Dyspnea (difficult or laboured breathing): 5 people, 31.25%
Fall: 5 people, 31.25%
Fluid Overload (too much fluid in the blood): 5 people, 31.25%

What are the existing conditions these people have? *

Portopulmonary Hypertension (coexistence of portal and pulmonary hypertension): 5 people, 31.25%
Gastritis Erosive (a break in the surface layer of the membrane lining the stomach with infection): 2 people, 12.50%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 12.50%
High Blood Pressure: 2 people, 12.50%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 2 people, 12.50%
Cough: 1 person, 6.25%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 6.25%
Ascites (accumulation of fluid in the abdominal cavity): 1 person, 6.25%
Blood Pressure Abnormal: 1 person, 6.25%
Bone Disorder: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Evista and have Hepatic encephalopathy?

- Check whether Hepatic encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Evista:

Evista (25,891 reports)

Browse all side effects of Evista:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (909 drugs)

Browse all the conditions that are associated with Hepatic encephalopathy:

Hepatic encephalopathy (1,264 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on raloxifene hydrochloride (the active ingredients of Evista) and Evista (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.